Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes

Xenobiotica

Volumn 35, Issue 6, 2005, Pages 589-602

  Nakashima, A ^a   Kawashita, H ^a   Masuda, N ^a   Saxer, C ^a   Niina, M ^a   Nagae, Y ^a   Iwasaki, K ^a,b  

^a NOVARTIS PHARMA K K   (Japan)

^b PFIZER INC   (United States)

Author keywords

Angiotensin II receptor antagonist; CYP; CYP2C9; Human liver microsomes; Valsartan

Indexed keywords

4 HYDROXYVALERYL VALSARTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 4A11; DICLOFENAC; DRUG METABOLITE; FURAFYLLINE; MEPHENYTOIN; QUINIDINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VALSARTAN;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INHIBITION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYDROXYLATION; LIVER MICROSOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; PROADIFEN; RECOMBINANT PROTEINS; TETRAZOLES; VALINE;

EID: 24144460282     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500158175     Document Type: Article

References (35)

1. Bindschedler M, Degen P, Flesch G, de Gasparo M, Preiswerk G. 1997. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. European Journal of Clinical Pharmacology 52:371-378.
2. Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S. 1997. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: Efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Journal of Human Hypertension 11:483-489.
3. Bort R, Mace K, Boobis A, Gomez-Lechon MJ, Pfeifer A, Castell J. 1999. Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways. Biochemical Pharmacology 58:787-796.
4. Bourrie M, Meunier V, Berger Y, Fabre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277:321-332.
5. Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, Wyld PJ, Lloyd P, Flesch G, Waldmeier F, Sioufi A, Mullins F. 1997. Pharmacokinetics of valsartan in patients with liver disease. Clinical Pharmacology and Therapeutics 62:272-278.
6. Clarke SE, Ayrton AD, Chenery RJ. 1994. Characterization of the inhibition of P4501A2 by furafylline. Xenobiotica 24:517-526.
7. Colussi DM, Parisot C, Rossolino ML, Brunner LA, Lefevre GY. 1997. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. Journal of Clinical Pharmacology 37:214-221.
8. Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F. 1996. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: A comparative study of the efficacy and safety against amlodipine. Clinical Pharmacology and Therapeutics 60:341-346.
9. Criscione L, Bradley WA, Bühlmayer P, Whitebread S, Glazer R, Lloyd P, Müller P, de Gasparo M. 1995. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovascular Drug Review 13:230-250.
10. Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HP, Wood J. 1993. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. British Journal of Pharmacology 110:761-771.
11. Czendlik CH, Sioufi A, Preiswerk G, Howald H. 1997. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol. European Journal of Clinical Pharmacology 52:451-459.
12. Fischer V, Johanson L, Heitz F, Tullman R, Graham E, Baldeck JP, Robinson WT. 1999. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metabolism and Disposition 27:410-416.
13. Flesch G, Muller P, Lloyd P. 1997. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. European Journal of Clinical Pharmacology 52:115-120.
14. Flesch G, Müller PH, Degen P, Lloyd P, Dieterle W. 1993. Repeated dose pharmacokinetics of valsartan, a new angiotensin-II antagonist, in healthy subjects. European Journal of Drug Metabolism and Pharmacokinetics 18:abst 256.
15. Franklin MR. 1977. Inhibition of mixed-function oxidation by substrates forming reduced cytochrome P-450 metabolic-intermediate complex. Pharmacology and Therapeutics A 2:227-245.
16. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. 1994. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743-1752.
17. Gonzalez FJ. 1992. Human cytochromes P450: Problems and prospects. Trends in Pharmacological Science 13:346-352.
18. Guengerich FP. 1994. Catalytic selectivity of human cytochrome P450 enzymes: Relevance to drug metabolism and toxicity. Toxicology Letters 70:133-138.
19. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F. 1996. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. Journal of Hypertension 14:1147-1151.
20. Horai Y, Ishizaki T. 1988. Pharmacogenetics and its clinical implications. Part II. Oxidation polymorphism. Rational Drug Therapy 22:1-8.
21. Leemann T, Transon C, Dayer P. 1993. Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sciences 52:29-34.
22. Markham A, Goa KL. 1997. Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs 54:299-311.
23. Müller P, Flesch G, de Gasparo M, Gasparini M, Howald H. 1997. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. European Journal of Clinical Pharmacology 52:115-120.
24. Müller P, Flesch G, de Gasparo M, Turri M, Preiswerk G, Howald H. 1993. Single and multiple dose phase I trials with the angiotensin II antagonist valsartan. Journal of Hypertension 12:S459.
25. Newton DJ, Wang RW, Lu AY. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 23:154-158.
26. Prasad P, Mangat S, Yeh CM, Glazer R. 1999. Lack of interaction between valsartan and digoxin in healthy subjects. American Journal of Hypertension 12(4 Part 2): 124A, abst D053.
27. Schenkman JB, Wilson BJ, Cinti DL. 1972. Dimethylaminoethyl 2,2-diphenylvalerate HCl (SKF 525-A)-in vivo and in vitro effects of metabolism by rat liver microsomes-formation of an oxygenated complex. Biochemical Pharmacology 21:2373-2383.
28. Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. 1998. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. European Journal of Clinical Pharmacology 53:451-458.
29. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, Davies DS. 1990. Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. British Journal of Clinical Pharmacology 29:651-663.
30. Taavitsainen P, Kiukaanniemi K, Pelkonen O. 2000. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. European Journal of Clinical Pharmacology 56:135-140.
31. Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P. 1996. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. European Journal of Clinical Pharmacology 51:79-85.
32. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27:59-71.
33. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. 1993. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2Cl9 and S-mephenytoin 4′-hydroxylation. Archives of Biochemistry and Biophysics 306:240-245.
34. Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T. 1998. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochemical Pharmacology 56:243-251.
35. Yamazaki H, Shimada T. 1998. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metabolism and Disposition 26:1053-1057.